Vor Biopharma Inc. (VOR)
Develops a fusion protein drug to treat autoimmune diseases like lupus and rheumatoid arthritis.
$20.00+0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago-52.4%
The outlook
VOR is trading near the lower end of its 52-week range, with the price above both its 50- and 200-day moving averages. Analysts overwhelmingly favor the stock with a Strong Buy consensus, and the average price target sits roughly 89% above the current level. The overall data leans distinctly bullish.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range29% of the way from its 52-week low to high
Price targetAvg target +89% vs current price
Analyst price target
~12-month · 8 analysts$37.88average target+89.4% vs now
Now $20.00
Low $18.00High $50.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.08B
52-wk high
$53.00
52-wk low
$6.50
50-day avg
$16.26
200-day avg
$15.75
Trailing P/E
—